FDA OKs Monthly Maintenance Dose for Leqembi

Published on January 27, 2025

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan’s Eisai and partner Biogen’s Alzheimer’s drug Leqembi, the companies said on Monday. The drug received standard U.S. approval in 2023 after showing it slowed cognitive decline in patients…

Read Full Article (External Site)